XML 44 R36.htm IDEA: XBRL DOCUMENT  v2.3.0.11
ALLIANCES AND COLLABORATIONS (Lilly) (Details) (USD $)
In Millions, unless otherwise specified
3 Months Ended 6 Months Ended
Jun. 30, 2011
Jun. 30, 2010
Jun. 30, 2011
Jun. 30, 2010
Dec. 31, 2010
Net sales $ 5,434 $ 4,768 $ 10,445 $ 9,575  
Other (income)/expense (31) (19) (169) 94  
Other intangible assets - upfront, milestone and other licensing payments 3,222   3,222   3,370
Lilly [Member] | ERBITUX [Member]
         
Net sales 173 172 338 338  
Lilly [Member] | ERBITUX [Member] | North America [Member]
         
Distribution fee, percentage of net sales 39.00%   39.00%    
Distribution fees and royalty expense 71 71 140 140  
Lilly [Member] | ERBITUX [Member] | Japan [Member] | Commercialization fee [Member]
         
Other (income)/expense (6) (11) (15) (19)  
Lilly [Member] | necitumumab [Member]
         
Research and development reimbursements to/(from) collaboration partner 4 2 6 5  
Lilly [Member] | necitumumab [Member] | Development Costs For United States Studies [Member]
         
Funding of development costs, percentage 55.00%   55.00%    
Lilly [Member] | necitumumab [Member] | Development Costs For Global Studies [Member]
         
Funding of development costs, percentage 27.50%   27.50%    
Lilly [Member] | necitumumab [Member] | Development Costs For Japan Studies [Member]
         
Funding of development costs, percentage 50.00%   50.00%    
Lilly [Member] | ERBITUX And Necitumumab [Member] | Upfront, milestone and other licensing payments [Member]
         
Amortization expense - upfront, milestone and other licensing payments 9 9 19 19  
Other intangible assets - upfront, milestone and other licensing payments 267   267   286
Lilly and Merck KGaA [Member] | ERBITUX [Member] | Japan [Member]
         
Percentage share of pre-tax profit/loss received from the net sales of a collaboration partner to be shared further equally with another collaboration partner. 50.00%   50.00%    
ERBITUX [Member]
         
Net sales $ 173 $ 172 $ 338 $ 338